Complexation Study of the Anticancer Agent EO-9 with 2-hydroxypropyl-β-Cyclodextrin

REFERENCES

• M. J. Arias, J. R. Moyano, P. Munoz, J. M. Gines, A. Justo, and F. Giordano. (2000). Study of omeprazole-gamma-cyclodextrin complexation in the solid state. Drug Dev. Ind. Pharm. 26:253–259.
   PubMed Web of Science ®Google Scholar
• N. Bandi, W. Wei, C. B. Roberts, L. P. Kotra, and U. B. Kompella. (2004). Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci. 23:159–168.
   PubMed Web of Science ®Google Scholar
• J. H. Beijnen, J. Den Hartigh, and W. J. M. Underberg. (1985). Qualitative aspects of the degradation of mitomycins in alkaline solution. J. Pharm. Biomed. Anal. 3:71–79.
   PubMed Web of Science ®Google Scholar
• K. A. Connors. (1995). Population characteristics of cyclodextrin complex stabilities in aqueous solution. J. Pharm. Sci. 84:843–848.
   PubMed Web of Science ®Google Scholar
• M. Echezarreta-Lopez, J. J. Torres-Labandeira, L. Castineiras-Seijo, L. Santana-Penin, and J. L. Vila-Jato. (2000). Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Sci. 9:381–386.
   PubMed Web of Science ®Google Scholar
• H. W. Frijlink, A. C. Eissens, N. R. Hefting, K. Poelstra, C. F. Lerk, and D. K. Meijer. (1991). The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res. 8:9–16.
   PubMed Web of Science ®Google Scholar
• S. Gibaud, S. B. Zirar, P. Mutzenhardt, I. Fries, and A. Astier. (2005). Melarsoprol-cyclodextrins inclusion complexes. Int. J. Pharm. 306:107–121.
   PubMed Web of Science ®Google Scholar
• G. Gladys, G. Claudia, and L. Marcela. (2003). The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Sci. 20:285–293.
   PubMed Web of Science ®Google Scholar
• S. Gould, and R. C. Scott. (2005). 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): A toxicology review. Food Chem. Toxicol. 43:1451–1459.
   PubMed Web of Science ®Google Scholar
• H. R. Hendriks, P. E. Pizao, D. P. Berger, K. L. Kooistra, M. C. Bibby, E. Boven, der Meulen HC Dreef-van, R. E. Henrar, H. H. Fiebig, and J. A. Double. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer 29A:897–906.
   PubMed Web of Science ®Google Scholar
• T. Higuchi, and K. A. Connors. (1965). Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4:117–212.
   Google Scholar
• T. Irie, and K. Uekama. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:147–162.
   PubMed Web of Science ®Google Scholar
• J. D. Jonkman-de Vries, J. Winkelhorst, W. J. M. Underberg, R. E. C. Henrar, and J. H. Beijnen. (1993). A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9. Int. J. of Pharm. 100:181–188.
   Web of Science ®Google Scholar
• T. Loftsson, D. Hreinsdottir, and M. Masson. (2005). Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302:18–28.
   PubMed Web of Science ®Google Scholar
• S. R. McKeown, R. L. Cowen, and K. J. Williams. (2007). Bioreductive drugs: From concept to clinic. Clin. Oncol. (R. Coll. Radiol.) 19:427–442.
   PubMed Web of Science ®Google Scholar
• S. P. Porras, K. Sarmini, S. Fanali, and E. Kenndler. (2003). Medium effect (transfer activity coefficient) of methanol and acetonitrile on beta-cyclodextrin/benzoate complexation in capillary zone electrophoresis. Anal. Chem. 75:1645–1651.
   PubMed Web of Science ®Google Scholar
• T. Pralhad, and K. Rajendrakumar. (2004). Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. J. Pharm. Biomed. Anal. 34:333–339.
   PubMed Web of Science ®Google Scholar
• V. M. Rao, and V. J. Stella. (2003). When can cyclodextrins be considered for solubilization purposes?. J. Pharm. Sci. 92:927–932.
   PubMed Web of Science ®Google Scholar
• L. S. Ribeiro, D. C. Ferreira, and F. J. Veiga. (2003). Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci. 20:253–266.
   PubMed Web of Science ®Google Scholar
• R. C. Rowe, S. C. Owen, and P. J. Sheskey. Handbook of pharmaceutical excipients5th. Pharmaceutical Press, London, (2006) .
   Google Scholar
• L. P. Ruan, B. Y. Yu, G. M. Fu, and D. N. Zhu. (2005). Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J. Pharm. Biomed. Anal. 38:457–464.
   PubMed Web of Science ®Google Scholar
• L. Szente, and J. Szejtli. (1999). Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28.
   PubMed Web of Science ®Google Scholar
• K. Uekama, F. Hirayama, and T. Irie. (1998). Cyclodextrin drug carrier systems. Chem. Rev. 98:2045–2076.
   PubMed Web of Science ®Google Scholar
• S. C. van der Schoot, B. Nuijen, F. M. Flesch, A. Gore, D. Mirejovsky, L. Lenaz, and J. H. Beijnen. (2007). Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS. PharmSciTech. 8:E61.
   PubMedGoogle Scholar
• S. C. van der Schoot, L. D. Vainchtein, J. H. Beijnen, A. Gore, D. Mirejovsky, L. Lenaz, and B. Nuijen. (2007). EO-9 bladder instillations: Formulation selection based on stability characteristics and in vitro simulation studies. Int. J. Pharm. 329:135–141.
   PubMed Web of Science ®Google Scholar
• F. Veiga, C. Fernandes, and P. Maincent. (2001). Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev. Ind. Pharm. 27:523–532.
   PubMed Web of Science ®Google Scholar
• X. Wen, F. Tan, Z. Jing, and Z. Liu. (2004). Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J. Pharm. Biomed. Anal. 34:517–523.
   PubMed Web of Science ®Google Scholar
• Y. Zheng, I. S. Haworth, Z. Zuo, M. S. Chow, and A. H. Chow. (2005). Physicochemical and structural characterization of quercetin-beta-cyclodextrin complexes. J. Pharm. Sci. 94:1079–1089.
   PubMed Web of Science ®Google Scholar
• G. Zingone, and F. Rubessa. (2005). Preformulation study of the inclusion complex warfarin-beta-cyclodextrin. Int. J. Pharm. 291:3–10.
   PubMed Web of Science ®Google Scholar